My Treatment Approach: My Treatment Approach: Navigating Genetic Testing and RET-Targeted Treatments in NSCLC - Episode 9

Role of Immunotherapy and Chemotherapy in RET-Positive NSCLC

,

Panelists discuss the situations in which other first-line therapies, such as cabozantinib or PD-L1–positive chemotherapy options, might be considered for RET fusion–positive non–small cell lung cancer (NSCLC), and compare the role of chemotherapy and immunotherapy to that of RET inhibitors in this setting.

EP. 1: Patient Case: 67 Year-Old Male With Stage IIIB+ NSCLC Awaiting for Mutation Testing
EP. 2: Next Steps to Stage IIIB NSCLC Patient Case Awaiting Molecular Testing and Usability of Liquid Biopsy
EP. 3: Testing Methodologies and Standards in Metastatic NSCLC
EP. 4: Practical Considerations in Metastatic NSCLC: Access and Timing of Testing
EP. 5: Clinical-Decision Making: When to Treat Advanced NSCLC Without Mutational Results
EP. 6: Initial Approach to Management of RET-Positive NSCLC
EP. 7: Patient and Therapy Considerations Guiding Initiation of Treatment in RET-Positive NSCLC
EP. 8: Considerations for First-Line Targeted Therapies in Metastatic RET-Positive NSCLC
Now Viewing
EP. 9: Role of Immunotherapy and Chemotherapy in RET-Positive NSCLC
EP. 10: Managing RET Inhibitor Treatment-Related Adverse Events
  1. Dr Sands to Dr Wakelee: In what situations do you consider other first-line therapies (eg, cabozantinib, PD-L1–positive chemotherapy options)?
    • What is the role of chemotherapy and/or immunotherapy currently in RET fusion–positive NSCLC? How does this compare to RET inhibitors?

Related Content:

My Treatment Approach: My Treatment Approach: Navigating Genetic Testing and RET-Targeted Treatments in NSCLC Video SeriesInsights
Implications of ESMO Guidelines for IGHV-Mutated vs Unmutated CLL
Managing RET Inhibitor Treatment-Related Adverse Events
Academic Perspectives in Front-Line Treatment Goals in Newly Diagnosed Transplant-Ineligible Multiple Myeloma